News >

Nab-Paclitaxel Plus Gemcitabine Misses DFS Endpoint in Pancreatic Cancer

Gina Columbus @ginacolumbusonc
Published: Tuesday, Mar 12, 2019

The adjuvant combination of nab-paclitaxel (Abraxane) and gemcitabine was not found to improve disease-free survival (DFS) compared with gemcitabine alone, as confirmed by independent radiological review, in patients with pancreatic cancer, according to topline findings of the phase III APACT trial (NCT01964430).1

Celgene added in the press release that there are currently more than 130 studies evaluating nab-paclitaxel in patients with pancreatic cancer in combination with more than 50 novel agents.

References

  1. Celgene Provides Update on ABRAXANE Combination Therapy in the Treatment of Metastatic Triple-Negative Breast Cancer and Pancreatic Cancer. Celgene. Published March 12, 2019. https://bit.ly/2HmHy2X. Accessed March 12, 2019.
  2. Hammel P, Lacy J, Portales F, et al. Phase II LAPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients with locally advanced pancreatic cancer (LAPC). J Clin Oncol. 2018;36 (suppl 4S; abstr 204). doi: 10.1200/JCO.2018.36.4_suppl.204

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x